Drugs / ARD-885
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07266207 | Dec 2024 → Aug 2025 | rheumatoid arthritis | Artivila (Shenzhen) Innovation Center, Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARD-885 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07266207 ↗ |
| Action | Inhibit | “dual-target inhibitor of IRAK4 and IRAK1” NCT07266207 ↗ |
| Target | IRAK4 | “ARD-885 Tablet is a dual-target inhibitor of IRAK4” NCT07266207 ↗ |